Insamo Launches with $12M Funding from Playground Global, venBio, and MRL Ventures Fund to Develop Best-in-Class Membrane-Permeable Macrocyclic Peptides

Insamo, a biotechnology company pioneering the discovery of membrane-permeable and orally available cyclic-peptides, today announced $12 million in seed capital from Playground Global, venBio, and MRL Ventures Fund (MRLV). MRLV is a corporate venture arm of Merck & Co., Inc which invests in early-stage, preclinical therapeutics companies.